Back to search

Belgium· BE-AMP-SAM547493-00

Giapreza 2.5 mg/ml

A angiotensin ii product containing angiotensin ii acetate, registered in Belgium by Paion Pharma. The same ATC class is registered in 11 of our 19 countries.

ATC C01CX09

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedGiapreza 2.5 mg/mlATCC01CX09REGISTER NO.BE-AMP-SAM547493-00PACKS LISTED0CHECKEDSeptember 26, 2026

Where it is registered

Angiotensin ii is registered in 11 of 19 countries.

Countries holding a registration under ATC C01CX09 (angiotensin ii), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose

Angiotensin ii · ATC C01CX09

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Angiotensin II Acetate
Manufacturer
Paion Pharma
Country
Belgium (BE)
ATC code
C01CX09
ATC class
Angiotensin II
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Angiotensin ii in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All angiotensin ii products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/152aace4-2045-4b37-bb61-c2f8b964f7f7
GET /v1/drugs/152aace4-2045-4b37-bb61-c2f8b964f7f7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Giapreza 2.5 mg/ml",
  "name_fr": "Giapreza 2.5 mg/ml",
  "name_nl": "Giapreza 2.5 mg/ml",
  "amp_code": "SAM547493-00",
  "strengths": [
    "2.5000",
    "2.5000",
    "2.5000"
  ],
  "pack_count": 1,
  "substances": [
    "Angiotensin II Acetate",
    "Angiotensin II",
    "Mannitol",
    "Sodium Hydroxide"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Angiotensin II",
  "authorisation_numbers": [
    "EU/1/19/1384/002"
  ]
}

See everything about angiotensin ii.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.